595 related articles for article (PubMed ID: 15269191)
1. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
Mathers Dunbar L; Hassman J; Tellier G
Clin Ther; 2004 Jan; 26(1):48-62. PubMed ID: 14996517
[TBL] [Abstract][Full Text] [Related]
3. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Tellier G; Chang JR; Asche CV; Lavin B; Stewart J; Sullivan SD
Curr Med Res Opin; 2004 May; 20(5):739-47. PubMed ID: 15140341
[TBL] [Abstract][Full Text] [Related]
4. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
Niederman MS; Chang JR; Stewart J; Nusrat R; Nieman RB
Curr Med Res Opin; 2004 May; 20(5):749-56. PubMed ID: 15140342
[TBL] [Abstract][Full Text] [Related]
5. Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis.
Buchanan P; Roos K; Tellier G; Rangaraju M; Leroy B
Int J Antimicrob Agents; 2005 Mar; 25(3):237-46. PubMed ID: 15737519
[TBL] [Abstract][Full Text] [Related]
6. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
Low DE; Brown S; Felmingham D
Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.
Norrby SR; Quinn J; Rangaraju M; Leroy B
Clin Microbiol Infect; 2004 Jul; 10(7):615-23. PubMed ID: 15214873
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.
Niederman MS; Chang JR; Stewart J; Asche CV; Lavin B; Nusrat R; Sullivan SD
Curr Med Res Opin; 2004 Jul; 20(7):969-80. PubMed ID: 15265241
[TBL] [Abstract][Full Text] [Related]
9. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.
Hagberg L; Carbon C; van Rensburg DJ; Fogarty C; Dunbar L; Pullman J
Respir Med; 2003 Jun; 97(6):625-33. PubMed ID: 12814146
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study.
Quinn J; Ruoff GE; Ziter PS
Clin Ther; 2003 Feb; 25(2):422-43. PubMed ID: 12749505
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia.
Hagberg L; Torres A; van Rensburg D; Leroy B; Rangaraju M; Ruuth E
Infection; 2002 Dec; 30(6):378-86. PubMed ID: 12478329
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Hoeffken G; Meyer HP; Winter J; Verhoef L;
Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
Walsh F; Carnegy F; Willcock J; Amyes S
J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
[TBL] [Abstract][Full Text] [Related]
14. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
15. Telithromycin.
Wellington K; Noble S
Drugs; 2004; 64(15):1683-94; discussion 1695-6. PubMed ID: 15257629
[TBL] [Abstract][Full Text] [Related]
16. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
Drago L; De Vecchi E; Nicola L; Colombo A; Gismondo MR
J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults.
Pullman J; Champlin J; Vrooman PS
Int J Clin Pract; 2003 Jun; 57(5):377-84. PubMed ID: 12846341
[TBL] [Abstract][Full Text] [Related]
18. Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
Fogarty CM; Buchanan P; Aubier M; Baz M; van Rensburg D; Rangaraju M; Nusrat R
Int J Infect Dis; 2006 Mar; 10(2):136-47. PubMed ID: 16183318
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.
Fogarty CM; Patel TC; Dunbar LM; Leroy BP
BMC Infect Dis; 2005 May; 5():43. PubMed ID: 15927060
[TBL] [Abstract][Full Text] [Related]
20. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]